Once the project assessment was completed, Sophic uncovered several gaps in critical documentation and user integration into the design. During the initial Formative test, Sophic identified several barriers for successful market adoption and usability barriers with the device. Specifically, the technology was utilizing many features accessible by a tablet that required a more advanced understanding and experience than the target user demographic possessed or desired to learn and integrate into their daily life. Further, the design of the watchband was difficult to use and prevented the users from placing it on their wrists due to neuropathies and struggles with the band clasp. As a result, Sophic worked with LIVMOR to reduce the complexity associated with the use of the technology. Allowing the user to easily attach the wristband and reduce the complexity of interaction that allowed the user to live normally without added tasks. This also created a device that could be consistently and successfully deployed and used by this population, allowing for accurate health monitoring and the potential for near real-time lifesaving interventions from the user’s medical team. The new device solution passed the Summative validation tests and received FDA regulatory approval. LIVMOR was later successfully acquired by HeartBeam.